Our group has recently demonstrated that a combinatorial Ad vector expressing a PD-L1 blocking mini-antibody (CAdVECPDL1) enhances the antitumor effect of HER2.CAR-T cells, which were recently reported to be safe in patients with sarcoma (43), against multiple human cancer cells in vitro and in vivo (35). Here, CD274 is linked to cancer.